Hematopoietic stem cell gene therapy
DW Emery, T Nishino, K Murata, M Fragkos… - International journal of …, 2002 - Springer
DW Emery, T Nishino, K Murata, M Fragkos, G Stamatoyannopoulos
International journal of hematology, 2002•SpringerGene therapy applications that target hematopoietic stem cells (HSCs) offer great potential
for the treatment of hematologic disease. Despite this promise, clinical success has been
limited by poor rates of gene transfer, poor engraftment of modified cells, and poor levels of
gene expression. We describe here the basic approach used for HSC gene therapy, briefly
review some of the seminal clinical trials in the field, and describe several recent advances
directed toward overcoming these limitations.
for the treatment of hematologic disease. Despite this promise, clinical success has been
limited by poor rates of gene transfer, poor engraftment of modified cells, and poor levels of
gene expression. We describe here the basic approach used for HSC gene therapy, briefly
review some of the seminal clinical trials in the field, and describe several recent advances
directed toward overcoming these limitations.
Abstract
Gene therapy applications that target hematopoietic stem cells (HSCs) offer great potential for the treatment of hematologic disease. Despite this promise, clinical success has been limited by poor rates of gene transfer, poor engraftment of modified cells, and poor levels of gene expression. We describe here the basic approach used for HSC gene therapy, briefly review some of the seminal clinical trials in the field, and describe several recent advances directed toward overcoming these limitations.
Springer